Table 1.
Patient characteristics
| HBV or HCV coinfected (n.28) | HIV + only (n. 281) | P value | |
|---|---|---|---|
| Age |
|
|
|
| Median (IQR) |
27.5 (23–30) |
27 (23–31) |
0.960 |
| WHO Stage N. (%) |
|
|
|
| I |
17 (63) |
211 (75.9) |
0.493 |
| II |
7 (25.9) |
47 (16.9) |
|
| III |
3 (11.1) |
19 (6.8) |
|
| IV |
|
1 (0.4) |
|
| Week of gestation at ART initiation |
|
|
|
| Median (IQR) |
27 (24–31) |
26 (24–30) |
0.576 |
| Duration of ART during pregnancy |
|
|
|
| Median days (IQR) |
78 (49–92) |
70 (44–95) |
0.828 |
| ART regimen, N. (%) |
|
|
|
| Stavudine/Lamivudine/Nevirapine |
15 (53.6) |
148 (52.7) |
|
| Zidovudine/Lamivudine/Nevirapine |
13 (46.4) |
133 (47.3) |
0.927 |
| Baseline Hemoglobin (g/dl) |
|
|
|
| Median (IQR) |
9.8 (9.0-10.9) |
10.3 (9.5-11.3) |
0.082 |
| Baseline Platelets (x103/mm3) |
|
|
|
| Median (IQR) |
177 (126–262) |
202 (168–249) |
0.106 |
| Baseline ALT (IU/ml) |
|
|
|
| Median (IQR) |
15.5 (12.2-27.1) |
12.5 (10–17.8) |
0.043 |
| Baseline AST (IU/ml) |
|
|
|
| Median (IQR) |
28 (23.3-37.1) |
25.1 (19.3-34.2) |
0.209 |
| Baseline CD4+ cell count/mm3 |
|
|
|
| Median (IQR) |
327 (193–495) |
340 (219–494) |
0.666 |
| Baseline HIV-RNA log10/ml |
|
|
|
| Median (IQR) | 3.89 (3.0-4.5) | 4.09 (3.4-4.6) | 0.297 |